Englander Institute for Precision Medicine

Publications

Found 840 results
Author Title Type [ Year(Asc)]
2023
Hsiehchen D, Bucheit L, Yang D, Beg MShaalan, Lim M, Lee SS, Kasi PMurtaza, Kaseb AO, Zhu H.  2023.  Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.. Nat Commun. 14(1):7621.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.
Hajirasouliha I, Semrau S.  2023.  Back in 3D-a report on Genome Informatics 2022.. Genome Biol. 24(1):57.
Boeck N, Trajanoski Z, Galluzzi L.  2023.  Bacterial antigens unleash tumor-targeting immunity.. Cell Host Microbe. 31(12):1945-1947.
Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, Lehmann CHK, Pan H, Paulhan N, Amon L et al..  2023.  BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.. Cancer Discov. 13(11):2448-2469.
Cultrara C, Uhl C, Kirby K, Elrazaq EAbed, Zellander A, Andrews DW, Scott CB, Galluzzi L, Exley MA, Zilberberg J.  2023.  A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.. J Immunother Cancer. 11(8)
Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A et al..  2023.  Bladder cancer organoids as a functional system to model different disease stages and therapy response.. Nat Commun. 14(1):2214.
Choi S, Whitman MA, Shimpi AA, Sempertegui ND, Chiou AE, Druso JE, Verma A, Lux SC, Cheng Z, Paszek M et al..  2023.  Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.. Nat Biomed Eng. 7(11):1455-1472.
Santambrogio L, Marrack P.  2023.  The broad spectrum of pathogenic autoreactivity.. Nat Rev Immunol. 23(2):69-70.
Dhaouadi N, Vitto VAngela Mar, Pinton P, Galluzzi L, Marchi S.  2023.  Ca signaling and cell death.. Cell Calcium. 113:102759.
Guilbaud E, Kroemer G, Galluzzi L.  2023.  Calreticulin exposure orchestrates innate immunosurveillance.. Cancer Cell. 41(6):1014-1016.
Galassi C, Galluzzi L.  2023.  Cancer stem cell immunoediting by IFNγ.. Cell Death Dis. 14(8):538.
Galluzzi L, Myint M.  2023.  Cell death and senescence.. J Transl Med. 21(1):425.
Weiss TJ, Crawford ER, Posada V, Rahman H, Liu T, Murphy BM, Arnold TE, Gray S, Hu Z, Hennessey RC et al..  2023.  Cell-intrinsic melanin fails to protect melanocytes from ultraviolet-mutagenesis in the absence of epidermal melanin.. Pigment Cell Melanoma Res. 36(1):6-18.
Klapp V, Buqué A, Bloy N, Sato A, Yamazaki T, Zhou XKathy, Formenti SC, Galluzzi L, Petroni G.  2023.  Cellular senescence in the response of HR breast cancer to radiotherapy and CDK4/6 inhibitors.. J Transl Med. 21(1):110.
Gao VR, Yang R, Das A, Luo R, Luo H, McNally DR, Karagiannidis I, Rivas MA, Wang Z-M, Barisic D et al..  2023.  ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.. bioRxiv.
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JPablo, Bellmunt J et al..  2023.  Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.. EClinicalMedicine. 60:101993.
Agarwal PK, Sternberg CN.  2023.  Clinical Trials Corner Issue 9 (2). Bladder Cancer. 9(2):187-190.
Agarwal PK, Sternberg CN.  2023.  Clinical Trials Corner Issue 9 (4). Bladder Cancer. 9(4):377-381.
Meleshko D, Prjbelski AD, Raiko M, Tomescu AI, Tilgner H, Hajirasouliha I.  2023.  cloudrnaSPAdes: Isoform assembly using bulk barcoded RNA sequencing data.. bioRxiv.
Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Vélez NEFélix, Abeles EB, Allam M, Hu T et al..  2023.  Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.. Nat Mater. 22(4):511-523.
Batra R, Krumsiek J, Wang X, Allen M, Blach C, Kastenmüller G, Arnold M, Ertekin-Taner N, Kaddurah-Daouk RF.  2023.  Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy.. medRxiv.